

## [Nifurtimox](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.5. Antitrypanosomal medicines](#) [6.5.5.2. American trypanosomiasis](#)

ATC codes: [P01CC01](#)

EMLc

Indication

Chagas disease ICD11 code: [1F53.Z](#)

INN

Nifurtimox

Medicine type

Chemical agent

List type

Core

Formulations

**Oral > Solid > tablet:** 30 mg (scored) ; 120 mg (scored)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1982 ([TRS 685](#))

Changed in 1987 ([TRS 770](#))

Changed in 2003 ([TRS 920](#))

Changed in 2007 ([TRS 950](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Nifurtimox](#)

DrugBank

[Nifurtimox](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the deletion of nifurtimox 250 mg tablets from the EML and EMLc.